Vertigo Management in Glaucoma Patients

First-Line Treatment Options

The American Academy of Otolaryngology-Head and Neck Surgery recommends avoiding betahistine in glaucoma patients as it should be used with caution in patients with asthma and peptic ulcer disease, and is completely contraindicated in patients with pheochromocytoma 1

Particle repositioning maneuvers should be the first-line treatment rather than medications, as they are more effective for BPPV, according to the American Academy of Otolaryngology-Head and Neck Surgery 2, 3
Vestibular suppressant medications are not routinely recommended for BPPV treatment except for short-term management of severe autonomic symptoms like nausea or vomiting, as suggested by the American Academy of Otolaryngology-Head and Neck Surgery 3, 4

Diuretics may be considered as maintenance therapy to reduce symptoms or prevent attacks, according to the American Academy of Otolaryngology-Head and Neck Surgery 5, 6, 7
However, carbonic anhydrase inhibitor diuretics should be avoided in glaucoma patients as they can affect intraocular pressure, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 5, 8
Intratympanic steroid therapy may be offered to patients with active Ménière's disease not responsive to noninvasive treatments, as suggested by the American Academy of Otolaryngology-Head and Neck Surgery 6, 9

Meclizine works as an antihistamine with a suppressive effect on the central emetic center to relieve nausea and vomiting associated with vertigo, according to the American Academy of Otolaryngology-Head and Neck Surgery 3
Betahistine has shown mixed results in clinical trials, with a well-designed BEMED trial finding no significant differences between betahistine and placebo in reducing vertigo attacks in Ménière's disease, as reported by the American Academy of Otolaryngology-Head and Neck Surgery 5, 10, 11
Common side effects of vestibular suppressant medications include drowsiness, cognitive deficits, and interference with driving or operating machinery, as noted by the American Academy of Otolaryngology-Head and Neck Surgery 2
Increased risk of falls, especially in elderly patients, is a significant concern with vestibular suppressant medications, according to the American Academy of Otolaryngology-Head and Neck Surgery 2

Patients should be reassessed within 1 month after initial treatment to document resolution or persistence of symptoms, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 2, 4
If oral medication is initiated, the patient should be monitored for improvement or stabilization of symptoms and for medication intolerance or side effects, according to the American Academy of Otolaryngology-Head and Neck Surgery 5, 11
Consider titrating down or stopping the medication once symptoms subside, as suggested by the American Academy of Otolaryngology-Head and Neck Surgery 5, 11

Vestibular suppressant medications are a significant independent risk factor for falls, especially in elderly patients or those taking multiple medications, as noted by the American Academy of Otolaryngology-Head and Neck Surgery 2
For patients with severe symptoms, short-term use of meclizine may be appropriate, but long-term use should be avoided due to potential side effects and interference with central compensation, according to the American Academy of Otolaryngology-Head and Neck Surgery 3, 4
If vertigo symptoms persist despite appropriate medication, consider referral to a specialist for further evaluation and management, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 6, 9